RLAY RELAY THERAPEUTICS INC Operational Disruptions 8-K Filing 2023 - Announcement Relay Therapeutics, Inc. announced full dose escalation data from their ReFocus trial for RLY-4008, an investigational inhibitor of FGFR2.Get access to all SEC 8-K filings of the RELAY THERAPEUTICS INC